The Scottish Medicines Consortium horizon scanning process plays an important role in providing NHS Scotland with intelligence on forthcoming medicines.
Patient Access Schemes in Scotland are specialised arrangements between pharmaceutical companies and NHS Scotland, designed to enhance the cost-effectiveness of new medicines.
The elements of a pharmaceutical company's Patient Access Scheme proposal to NHS Scotland, required to facilitate thorough evaluation by the Patient Access Scheme Assessment Group and the Scottish Medicines Consortium.
The Scottish Medicines Consortium follows a structured, typically 18-week, timeline in its health technology assessment process. We provide a breakdown of the different phases with associated timeframes.
The Scottish Medicines Consortium provides advice to NHS boards and their Area Drug and Therapeutics Committees (ADTCs) across Scotland about the status of all newly licensed medicines and all new formulations and new indications of established products. This Briefing outlines the standard process for newly licensed medicines.
The Scottish Medicines Consortium (SMC) offers an Interim Acceptance decision option as a potential outcome of its usual appraisal process, to provide patients in Scotland with early access to new medicines while additional evidence is gathered.
The Scottish Medicines Consortium has modernised the standard contractual terms for pricing agreements, clarifying the legal obligations for health boards and suppliers across NHS Scotland.
